

Claims

1. A composition comprising a PDE10A inhibitor for use in the prevention, management and/or treatment of inflammatory bowel diseases.
2. The composition for use according to claim 1, wherein the inflammatory bowel disease is ulcerative colitis.
3. The composition for use according to either claim 1 or 2, wherein the PDE10A inhibitor is a selective inhibitor of PDE10A.
4. The composition for use according to any preceding claim, wherein the PDE10A inhibitor is selected from one or more of the following: PF-02545920, TAK-063, Papaverine, RG7203, JNJ-42314415, AMG-579, PQ-10, BMS-843496, PDM-042 and derivatives thereof.
5. The composition for use according to any preceding claim, wherein the PDE10A inhibitor is selected from PF-02545920 or TAK-063.
6. The composition for use according to any preceding claim, wherein the PDE10A inhibitor selectively inhibits cGMP hydrolysis over cAMP hydrolysis.
7. The composition for use according to any preceding claim, wherein the management and/or treatment of inflammatory bowel diseases of the present invention involves increasing cGMP signalling in bowel tissue of a patient.
8. The composition for use according to any preceding claim, wherein the management and/or treatment of inflammatory bowel diseases of the present invention involves reducing levels of inflammatory cytokines in bowel tissue of a patient.
9. An inhibitor of PDE10A for use in the prevention, management and/or treatment of inflammatory bowel diseases.
10. The inhibitor for use according to claim 9, wherein the inflammatory bowel disease is ulcerative colitis.

11. The inhibitor for use according to either claim 9 or 10, wherein the PDE10A inhibitor is a selective inhibitor of PDE10A.
12. The inhibitor for use according to any one of claims 9 to 11, wherein the PDE10A inhibitor is selected from one or more of the following: PF-02545920, TAK-063, Papaverine, RG7203, JNJ-42314415, AMG-579, PQ-10, BMS-843496, PDM-042 and derivatives thereof.
13. A method of prevention, management and/or treatment of inflammatory bowel diseases comprising the administration of a PDE10A inhibitor in an individual in need of such prevention, management and/or treatment.
14. The method according to claim 13, wherein the inflammatory bowel disease is ulcerative colitis.
15. The method according to either claim 13 or 14, wherein the PDE10A inhibitor is a selective inhibitor of PDE10A.
16. The method according to any one of claims 13 to 15, wherein the PDE10A inhibitor is selected from one or more of the following: PF-02545920, TAK-063, Papaverine, RG7203, JNJ-42314415, AMG-579, PQ-10, BMS-843496, PDM-042 and derivatives thereof.
17. The method according to any one of claims 13 to 16, wherein the PDE10A inhibitor is selected from PF-02545920 or TAK-063.
18. Use of an inhibitor of PDE10A in the manufacture of a medicament for the prevention, management and/or treatment of inflammatory bowel disease in an individual.
19. Use according to claim 18, wherein the inflammatory bowel disease is ulcerative colitis.
20. Use according to either claim 18 or 19, wherein the PDE10A inhibitor is a selective inhibitor of PDE10A.

21. Use according to any one of claims 18 to 20, wherein the PDE10A inhibitor is selected from one or more of the following: PF-02545920, TAK-063, Papaverine, RG7203, JNJ-42314415, AMG-579, PQ-10, BMS-843496, PDM-042 and derivatives thereof.